The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income from continuing operations | 16,748 | 16,639 |
| Share-based compensation | 4,919 | 9,014 |
| Depreciation and amortization | 5,290 | 6,371 |
| Deferred income taxes | -5,751 | -908 |
| Credit loss expense | 2,056 | 1,093 |
| Non-cash lease expenses | 318 | 619 |
| Shares received in settlement of litigation | 0 | 0 |
| Loss on extinguishment of debt | 0 | 0 |
| Other | 249 | 294 |
| Accounts receivable | 11,014 | 14,493 |
| Inventory | 1,612 | 1,083 |
| Prepaid expenses | -615 | -155 |
| Other assets | 3,440 | 2,261 |
| Accounts payable | 2,913 | 792 |
| Accrued compensation | 6,362 | -791 |
| Accrued expenses | 284 | 3,528 |
| Other liabilities | -110 | -1,067 |
| Net cash flows from operating activities of continuing operations | 29,329 | 19,718 |
| Net cash flows used in operating activities of discontinued operations | 0 | 0 |
| Net cash flows provided by operating activities | 29,329 | 19,718 |
| Cash paid for acquisitions | 3,064 | 700 |
| Purchases of equipment | 192 | 556 |
| Patent application costs | 2 | 37 |
| Other investments | 2,000 | - |
| Net cash flows used in investing activities | -5,258 | -1,293 |
| Stock repurchased for tax withholdings on vesting of restricted stock | 83 | 2,984 |
| Principal payment on citizens term loan facility | -250 | -500 |
| Cash paid for profit share payment (note 12) | 524 | 488 |
| Proceeds from citizens revolving credit facility | 0 | 0 |
| Proceeds from citizens term loan facility | 0 | 0 |
| Prepayment premium on previous term loan | 0 | 0 |
| Deferred financing cost | 0 | 0 |
| Repayment of previous term loan | 0 | 0 |
| Repayment of citizens revolving credit facility | 0 | 0 |
| Proceeds from exercise of stock options | 0 | 0 |
| Principal payments on finance lease | 0 | 0 |
| Net cash flows used in financing activities | -857 | -3,972 |
| Net change in cash | 23,214 | 14,453 |
| Cash and cash equivalents at beginning of period | 104,416 | - |
| Cash and cash equivalents at end of period | 142,083 | - |
MIMEDX GROUP, INC. (MDXG)
MIMEDX GROUP, INC. (MDXG)